Regeneron's Profit Falls as Expenses Spike

Date : 08/06/2019 @ 11:27AM
Source : Dow Jones News
Stock : Regeneron Pharmaceuticals Inc (REGN)
Quote : 344.24  -0.22 (-0.06%) @ 4:59AM

Regeneron's Profit Falls as Expenses Spike

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Regeneron Pharmaceuticals Charts.
   By Allison Prang 

Regeneron Pharmaceuticals Inc.'s (REGN) profit fell as expenses rose over 60%.

Earnings were $193.1 million, down 65% from the comparable quarter a year prior. Earnings were $1.68 a share, down from $4.82 a share.

Adjusted earnings were $6.02 a share, up from $5.45 a share. Analysts polled by FactSet were expecting $5.42 a share.

Revenue was $1.93 billion, up 20%. Analysts were expecting $1.8 billion.

Expenses rose 64%. Expenses for research and development almost doubled, which Regeneron said was mainly because of an up-front payment of $400 million for its Alnylam Pharmaceuticals Inc. (ALNY) collaboration agreement.


Write to Allison Prang at


(END) Dow Jones Newswires

August 06, 2019 07:12 ET (11:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.